Compare Merck & Co., Inc. (MRK) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs SMX Security Matters plc — how do they compare? Merck & Co., Inc. trades at $133.67 (market cap $321.77B), while SMX Security Matters plc trades at $16.48 (market cap $17.04M). The key difference: Merck & Co., Inc. is far larger — about 18883.2× SMX Security Matters plc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while SMX Security Matters plc pays none. Which is the better fit depends on your goals.
| MRK | SMX | |
|---|---|---|
Market Cap | $321.77B | $17.04M |
Sector | Health | Technology |
52-Week High | $131.84 | $103.71K |
52-Week Low | $77.60 | $12.87 |
Enterprise Value | $368.53B | -$14.29M |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
SMX trades at $16.45, up 4.11% today, amid a reverse stock split effective June 1, 2026. The stock shows bearish technical signals with support at $16 and resistance at $17. Financially, the company reported a net loss of $169.18 million for 2025, with negative ROE and ROA, though it strengthened its balance sheet with $77 million in financing in 2026. Recent news highlights SMX's focus on recycled plastic verification and commercialization strategies.
The outlook remains speculative; SMX's technology addresses growing demand for material traceability, but persistent losses and high cash burn pose significant risks. Investor sentiment is cautious due to weak profitability, though institutional financing provides near-term liquidity. The stock's viability hinges on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
